**List of Key References in Colon Cancer Screening**

Provided by:
David Ransohoff, MD

Medicine: Mind the Gap Seminar
Making Guidelines for Colon Cancer Screening: Evidence, Policy, and Politics
September 27, 2016


Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-1633.

Eden J, Levit L, Berg A, Morton S, eds. *Finding What Works in Health Care: Standards for Systematic Reviews.* Washington, DC: National Academies Press; 2011.

Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E, eds. Clinical practice guidelines we can trust. Washington DC: Institute of Medicine; The National Academies Press; 2011.

Hardcastle JD, Justin TA. Screening high-risk groups for colorectal neoplasia. Am J Gastroenterol 1996;91:850-852.

Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370(14):1287-1297.

Kaminski MF, Bretthauer M, Zauber AG, et al. The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy 2012;44(7):695-702.

Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348(9040):1467-1471.

Kung J, Miller RR, Mackowiak PA. Failure of clinical practice guidelines to meet Institute of Medicine standards: two more decades of little, if any, progress. *Arch Intern Med*. 2012;172(21):1628-1633.

Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 2014;160(3):171.

Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58(3):130-160.

Lin KW, Gostin LO. A public health framework for screening mammography: evidence-based vs. politically mandated care. *JAMA*. 2016;315(10):977- 978.

Lin JS, Piper MA, Perdue LA, Rutter CM, Webber EM, O'Connor E, Smith N, Whitlock EP. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016;315(23):2576-2594, PMID 27305422

Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328(19):1365-1371.

Pignone M, Russell L, Wagner J. Economic models of colorectal cancer screening in average-risk adults: workshop summary http://www.nap.edu/catalog/11228.html. Washington, DC: National Academies Press; 2005.

Ransohoff DF, Pignone M, Sox HC. How to decide whether a clinical practice guideline is trustworthy. JAMA 2013;309(2):139-140, PMID 23299601

Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012;366(25):2345-2357.

US Preventive Services Task Force. Draft recommendation statement – colorectal cancer: screening. http://www .uspreventiveservicestaskforce.org/Page /Document/draft-recommendation-statement38 /colorectal-cancer-screening2. October 2015. Accessed May 31, 2016.

US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, Jr., Garcia FA, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2016;315(23):2564-2575, PMID 27304597

Wilschut JA, Habbema JD, van Leerdam ME, et al. Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst 2011;103(23):1741-1751.

Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997;112(2):594-642.

Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329(27):1977-1981.

Woolf SH, Campos-Outcalt D. Severing the link between coverage policy and the US Preventive Services Task Force. *JAMA*. 2013;309(18):1899-1900.

Young GP, Symonds EL, Allison JE, et al. Advances in fecal occult blood tests: the FIT revolution. Dig Dis Sci 2015;60(3):609-622.

Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Kuntz KM. Evaluating the benefits and harms of colorectal cancer screening strategies: a collaborative modeling approach. AHRQ Publication 14-05203-EF-2 2015. http://www .uspreventiveservicestaskforce.org/Page /Document/modeling-report/colorectal-cancer -screening2. October2015. Accessed May 31, 2016.

Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of Colorectal-Cancer Deaths. N Engl J Med 2012; 366(8):687-696.